Related references
Note: Only part of the references are listed.Sphingosine 1-phosphate: A Potential Molecular Target for Ovarian Cancer Therapy?
Lan Dai et al.
CANCER INVESTIGATION (2014)
Current Approaches and Challenges in Managing and Monitoring Treatment Response in Ovarian Cancer
Charlotte S. Marcus et al.
JOURNAL OF CANCER (2014)
Targeting TBP-associated factors in ovarian cancer
Jennifer R. Ribeiro et al.
FRONTIERS IN ONCOLOGY (2014)
Angiogenesis-Related Pathways in the Pathogenesis of Ovarian Cancer
Nikos G. Gavalas et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Sorafenib Inhibits Epithelial-Mesenchymal Transition through an Epigenetic-Based Mechanism in Human Lung Epithelial Cells
Juyong Zhang et al.
PLOS ONE (2013)
Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer
Bengt Sorbe et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2012)
Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
Beth Y. Karlan et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Combined Weekly Topotecan and Biweekly Bevacizumab in Women With Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer Results of a Phase 2 Study
Kathryn F. McGonigle et al.
CANCER (2011)
Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers
Kazuya Kudoh et al.
GYNECOLOGIC ONCOLOGY (2011)
Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
Daniela Matei et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer
Robert L. Coleman et al.
LANCET ONCOLOGY (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The inherited genetics of ovarian and endometrial cancer
Simon A. Gayther et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2010)
Molecular characterization of ovarian cancer by gene-expression profiling
C. Gomez-Raposo et al.
GYNECOLOGIC ONCOLOGY (2010)
Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin
Akiko Hayashi et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
The genesis and evolution of high-grade serous ovarian cancer
David D. L. Bowtell
NATURE REVIEWS CANCER (2010)
Ovarian Cancer
Kathleen R. Cho et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways
Jung Jin Hwang et al.
ANTI-CANCER DRUGS (2009)
KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay
Veronika Auner et al.
BMC CANCER (2009)
Ovarian ablation by radiation therapy: Is it still an option for the ablation of ovarian function in endocrine responsive premenopausal breast cancer patients?
Nuran S. Bese et al.
BREAST (2009)
The temporal stability of the Symptom Index among women at high-risk for ovarian cancer
Kimberly A. Lowe et al.
GYNECOLOGIC ONCOLOGY (2009)
Histone Deacetylase Inhibitors in Cancer Therapy
Andrew A. Lane et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism
D. Mottet et al.
ONCOGENE (2009)
Regulation of Histone Acetylation in the Nucleus by Sphingosine-1-Phosphate
Nitai C. Hait et al.
SCIENCE (2009)
ROMIDEPSIN FOR THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA
Clara Campas-Moya
DRUGS OF TODAY (2009)
The biology of ovarian cancer: new opportunities for translation
Robert C. Bast et al.
NATURE REVIEWS CANCER (2009)
Loss of E-cadherin promotes ovarian cancer metastasis via alpha(5)-integrin, which is a therapeutic target
Kenjiro Sawada et al.
CANCER RESEARCH (2008)
Valproic acid resensitizes cisplatin-resistant ovarian cancer cells
Ching-Tai Lin et al.
CANCER SCIENCE (2008)
Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs
Kei-ichi Ozaki et al.
CANCER SCIENCE (2008)
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome
Richard W. Tothill et al.
CLINICAL CANCER RESEARCH (2008)
Histone deacetylases 1 and 2 are expressed at distinct stages of neuro-glial development
Jessica L. MacDonald et al.
DEVELOPMENTAL DYNAMICS (2008)
p21 and p27: roles in carcinogenesis and drug resistance
Abde M. Abukhdeir et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2008)
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
Susan C. Modesitt et al.
GYNECOLOGIC ONCOLOGY (2008)
P53 and bcl-2 assessment in serous ovarian carcinoma
J. E. Palmer et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)
Infertility as a Cancer Risk Factor - A Review
I. Cetin et al.
PLACENTA (2008)
Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas
Wilko Weichert et al.
NEOPLASIA (2008)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Role for histone deacetylase 1 in human tumor cell proliferation
Silvia Senese et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Intraperitoneal chemotherapy for patients with advanced ovarian cancer: A review of the evidence and standards for the delivery of care
M. Fung-Kee-Fung et al.
GYNECOLOGIC ONCOLOGY (2007)
Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth - Implications for therapy
Dineo Khabele et al.
CANCER BIOLOGY & THERAPY (2007)
Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer
Simon A. Gayther et al.
CANCER RESEARCH (2007)
Development of an ovarian cancer symptom index - Possibilities for earlier detection
Barbara A. Goff et al.
CANCER (2007)
Endogenous androgens and risk of epithelial ovarian cancer: Results from the European prospective investigation into cancer and nutrition (EPIC)
Sabina Rinaldi et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
Human endometrial and ovarian cancer cells: Histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis
Noriyuki Takai et al.
CURRENT MEDICINAL CHEMISTRY (2007)
PTEN mutation, expression and LOH at its locus in ovarian carcinomas.: Relation to TP53, K-RAS and BRCA1 mutations
I. K. Kolasa et al.
GYNECOLOGIC ONCOLOGY (2006)
Ovarian cancer: a focus on management of recurrent disease
Thomas J. Herzog et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies
Xiaozhong Qian et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients
Juergen Sonnemann et al.
BMC CANCER (2006)
Histone deacetylase 3 (HDAC3) and other class IHDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer
AJ Wilson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intrapentoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group study
JL Walker et al.
GYNECOLOGIC ONCOLOGY (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients
YV Shebzukhov et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
AZD2171:: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
SR Wedge et al.
CANCER RESEARCH (2005)
Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides
A Mai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Ovarian cancer metastasis: Integrating insights from disparate model organisms
H Naora et al.
NATURE REVIEWS CANCER (2005)
Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1
BH Huang et al.
CELL DEATH AND DIFFERENTIATION (2005)
Mechanisms of platinum drug resistance
M Ohmichi et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2005)
Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors
S Grégoire et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
D Strumberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Histologic types of epithelial ovarian cancer: have they different risk factors?
AW Kurian et al.
GYNECOLOGIC ONCOLOGY (2005)
Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer
DM Dinulescu et al.
NATURE MEDICINE (2005)
Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma
MM Leitao et al.
GYNECOLOGIC ONCOLOGY (2004)
Cultures of ovarian surface epithelium from women with and without a hereditary predisposition to develop female adnexal carcinoma
JMJ Piek et al.
GYNECOLOGIC ONCOLOGY (2004)
Molecular mechanisms of platinum resistance: still searching for the Achilles' heel
RP Wernyj et al.
DRUG RESISTANCE UPDATES (2004)
Human ovarian carcinoma cells: Histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis
N Takai et al.
CANCER (2004)
Cancer of the ovary
SA Cannistra
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Histone deacetylase inhibitors: Understanding a new wave of anticancer agents
A Villar-Garea et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor
A Vannini et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis
P Zhu et al.
CANCER CELL (2004)
Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: A Gynecologic Oncology Group Study
L Havrilesky et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice
HL Cheng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens
J Plisiecka-Halasa et al.
ANNALS OF ONCOLOGY (2003)
Class II histone deacetylases: versatile regulators
E Verdin et al.
TRENDS IN GENETICS (2003)
Identification of novel isoform-selective inhibitors within class I histone deacetylases
ED Hu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
A systematic overview of radiation therapy effects in ovarian cancer
N Einhorn et al.
ACTA ONCOLOGICA (2003)
Enzymatic activity associated with class IIHDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR
W Fischle et al.
MOLECULAR CELL (2002)
Histone deacetylases and cancer: Causes and therapies
PA Marks et al.
NATURE REVIEWS CANCER (2001)
Expression profile of histone deacetylase 1 in gastric cancer tissues
JH Choi et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2001)
Diet and ovarian cancer risk: A case-control study in Italy
C Bosetti et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Current and future potential roles of the platinum drugs in the treatment of ovarian cancer
MJ Piccart et al.
ANNALS OF ONCOLOGY (2001)
Mechanisms of resistance to cisplatin
M Kartalou et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2001)
Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked ovarian cancer
M Markman
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2001)
The language of covalent histone modifications
BD Strahl et al.
NATURE (2000)
Share Paper
